SUMMARY
Budesonide, the active component of PULMICORT RESPULES®, is a corticosteroid.
PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
PULMICORT RESPULES is NOT indicated for the relief of acute bronchospasm.
|
NEWS HIGHLIGHTS
Published Studies Related to Pulmicort Respules (Budesonide)
Budesonide foam induces remission in patients with mild to moderate ulcerative
proctitis and ulcerative proctosigmoiditis. [2015]
remission in patients with ulcerative proctitis or ulcerative proctosigmoiditis... CONCLUSIONS: Budesonide rectal foam was well tolerated and more efficacious than
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative
colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. [2015]
budesonide MMX in patients with mild-to-moderate active UC... CONCLUSION: This pooled analysis showed that budesonide MMX 9 mg is efficacious,
Effects of nebulized high-dose budesonide on moderate-to-severe acute
exacerbation of asthma in children: a randomized, double-blind,
placebo-controlled study. [2013]
exacerbation of asthma... CONCLUSION: On the basis of nebulized short-acting bronchodilators, addition of
Safety and Tolerability of High-Dose Budesonide/Formoterol via Turbuhaler(R) in Japanese Patients with Asthma: A Randomized, Double-Blind, Crossover, Active Comparator-Controlled, Phase III Study. [2012.01.01]
Background: The use of budesonide/formoterol as both maintenance and reliever therapy in asthma is recommended in many countries; however, there are limited data available for the Asian patient population. Objective: This study aimed to evaluate the short-term safety and tolerability of a fixed high-dose combination of the inhaled corticosteroid budesonide and the long-acting beta(2)-adrenoceptor agonist formoterol with that of the beta(2)-agonist terbutaline for acute symptom relief in Japanese adults with persistent asthma who were already receiving a combination of budesonide/formoterol maintenance therapy...
Abatacept for Crohn's disease and ulcerative colitis. [2012]
modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown... CONCLUSIONS: The studies showed that abatacept is not efficacious for the
Clinical Trials Related to Pulmicort Respules (Budesonide)
Pulmicort Respules on Relapse Rates After Treatment in the ED [Withdrawn]
The purpose of this study is to see if the addition of budesonide to oral corticosteroids
will result in a decrease in relapse rates compared to oral corticosteroids alone in
children who are discharged from the ED after an asthma exacerbation. Secondly, that there
will be an improvement in lung function, a decrease in beta-2 agonist use and an improvement
in health-related quality of life compared to placebo.
Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth [Recruiting]
Children with mild persistent asthma that have asthma symptoms once or twice a week and use
a daily controller, while children with mild intermittent asthma rarely have asthma symptoms
and do not use a daily controller. Inhaled corticosteroids are the standard treatment for
mild peristent asthma. The purpose of this study is to measure children rate of growth
while on different inhaled corticosteroids.
Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children [Completed]
A one year study comparing the safety and effectiveness of Pulmicort (0. 5mg strength given
once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the
evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children
aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will
receive 5mg strength SINGULAR.
Long-Term Safety of Symbicort in Asthmatic Children - SAPLING [Completed]
Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort
when given to asthma patients aged 12 years and above.
|
